- Tempus AI, Inc. (TEM, Financial) launches Tempus Loop, an AI-driven oncology platform for target discovery and validation.
- Loop utilizes real-world patient data, human biological modeling, and CRISPR screens to enhance precision medicine.
- The platform aims to reduce the 90% failure rate of preclinical assets transitioning to real-world treatments.
Tempus AI, Inc. (TEM), a technology leader in AI-driven precision medicine, has unveiled Tempus Loop, a cutting-edge platform to revolutionize oncology target discovery and validation. The proprietary platform uniquely combines real-world patient data (RWD), human-derived biological models, and CRISPR screens. This integration aids in identifying and validating novel therapeutic targets to expedite the drug discovery process.
The Loop platform addresses a critical challenge in transforming promising preclinical experiments into effective patient treatments. Traditional methods, which often rely on cell lines or animal models, are frequently poor predictors of human tumor responses. In contrast, Loop leverages Tempus' extensive RWD to identify patient subpopulations with similar clinical and molecular profiles. Systems biological approaches then highlight novel target genes and multimodal signatures, aligning patient subcohorts with relevant patient-derived organoids (PDOs) for further validation.
This innovative approach has already seen successful deployment, prioritizing drug targets for a major pharmaceutical client by utilizing its lab-in-the-loop strategy. The platform's integration of high-throughput functional screens has substantially accelerated standard discovery timelines, confirming and validating targets within a year.
Dr. Kate Sasser, Chief Scientific Officer at Tempus, emphasized the platform's impact, stating, "Despite increased R&D spending, the industry faces a 90% failure rate for preclinical assets. The Loop platform integrates vast multimodal patient data with advanced models and AI tools, enhancing both the speed and confidence in discovering clinically relevant targets."
Tempus continues to lead the way in precision medicine, providing AI-enabled solutions to facilitate personalized patient care and the development of optimal therapeutics. For further information, visit Tempus' official website.
